Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

BACKGROUND: In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy. This led to a phase 1b clinical trial to determine the safety, tolerability, and immunologic effects of ibrutinib treatment in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Meenal, Betts, Courtney, Zhang, Li, Griffith, Madeline J, Solman, Isabelle, Chen, Brandon, Liu, Eric, Tamaki, Whitney, Stultz, Jacob, Marquez, Jaqueline, Sivagnanam, Shamilene, Cheung, Alexander, Pener, Denise, Fahlman, Anne, Taber, Erin, Lerner, Kimberly, Crocker, Matthew, Todd, Kendra, Rajagopalan, Brindha, Ware, Clarisha, Bridge, Mark, Vo, Johnson, Dragomanovich, Hannah, Sudduth-Klinger, Julie, Vaccaro, Gina, Lopez, Charles D, Tempero, Margaret, Coussens, Lisa M, Fong, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809229/
https://www.ncbi.nlm.nih.gov/pubmed/36593070
http://dx.doi.org/10.1136/jitc-2022-005425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809229/
https://www.ncbi.nlm.nih.gov/pubmed/36593070
http://dx.doi.org/10.1136/jitc-2022-005425

Ejemplares similares